Featured
FDA Approves First In Vivo CRISPR Gene Therapy for Alzheimer’s Disease, Marking a New Era in Neurodegenerative Treatment
The FDA has approved NeuroEdit-AD, the first in vivo CRISPR gene therapy for Alzheimer's disease. This single-administration treatment crosses the blo...
Read Full Story →